Halozyme Therapeutics, Inc. $HALO Shares Bought by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 96.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,569,559 shares of the biopharmaceutical company’s stock after purchasing an additional 768,976 shares during the period. Halozyme Therapeutics comprises approximately 0.8% of Jupiter Asset Management Ltd.’s portfolio, making the stock its 26th largest holding. Jupiter Asset Management Ltd.’s holdings in Halozyme Therapeutics were worth $105,631,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the company. Root Financial Partners LLC acquired a new stake in Halozyme Therapeutics in the third quarter valued at approximately $25,000. Larson Financial Group LLC grew its holdings in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares in the last quarter. Clearstead Advisors LLC increased its position in shares of Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 265 shares during the last quarter. Harbour Investments Inc. raised its holdings in shares of Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 372 shares in the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth $52,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the transaction, the director owned 38,498 shares in the company, valued at approximately $2,443,853.04. This represents a 4.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $69.19, for a total transaction of $691,900.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $53,122,698.20. This trade represents a 1.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 120,482 shares of company stock worth $8,200,842 over the last 90 days. 2.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently commented on HALO. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. HC Wainwright lifted their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Morgan Stanley dropped their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Finally, Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $80.67.

Halozyme Therapeutics Stock Down 0.7%

Shares of NASDAQ:HALO opened at $68.18 on Friday. Halozyme Therapeutics, Inc. has a 1-year low of $51.06 and a 1-year high of $82.22. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The stock has a market cap of $8.09 billion, a P/E ratio of 24.53, a P/E/G ratio of 0.28 and a beta of 0.89. The firm has a fifty day moving average price of $66.09 and a 200 day moving average price of $68.77.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.6 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.